Similar articles

• Verification bias and the prostate-specific antigen test--is there a case for a lower threshold for biopsy?

  Schröder FH, Kranse R. Schröder FH, et al. N Engl J Med. 2003 Jul 24;349(4):393-5. doi: 10.1056/NEJMe030073. N Engl J Med. 2003. PMID: 12878747 No abstract available.
• Verification bias in screening for prostate cancer.

  Leiner S. Leiner S. N Engl J Med. 2003 Oct 23;349(17):1672-3; author reply 1672-3. doi: 10.1056/NEJM200310233491717. N Engl J Med. 2003. PMID: 14573742 No abstract available.
• Prostate cancer screening: is it possible to explain diametrically opposed views?

  Richardson A. Richardson A. N Z Med J. 2005 Feb 11;118(1209):U1289. N Z Med J. 2005. PMID: 15711622 No abstract available.
• [Two major diagnostic innovations in the management of prostate cancer].

  Doublet JD, Cornu JN, Rouprêt M. Doublet JD, et al. Prog Urol. 2007 Apr;17(2 Suppl 1):285-6. Prog Urol. 2007. PMID: 17569271 Review. French. No abstract available.
• Screening for prostate cancer.

  Postma R, Schröder FH. Postma R, et al. Eur J Cancer. 2005 Apr;41(6):825-33. doi: 10.1016/j.ejca.2004.12.029. Eur J Cancer. 2005. PMID: 15808952 Review.